Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg may leads to higher participants free from disability worsening compared with placebo (low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.07 [1.02, 1.11]
2 studies · 1556 participants
Low

Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.02 [0.99, 1.06]
1 study · 860 participants
Low